Compare GLBS & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | LITS |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | Greece | United States |
| Employees | N/A | 4 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 40.8M |
| IPO Year | 2010 | N/A |
| Metric | GLBS | LITS |
|---|---|---|
| Price | $2.15 | $1.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 67.4K | ★ 386.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.03 | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.95 |
| 52 Week High | $2.12 | $3.03 |
| Indicator | GLBS | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 68.96 | 44.79 |
| Support Level | $1.06 | $0.95 |
| Resistance Level | N/A | $1.16 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 100.00 | 57.45 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.